ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Otonomy Inc

Otonomy Inc (OTIC)

0.077
0.00
(0.00%)
終了 11月29日 6:00AM
0.00
0.00
(0.00%)
取引時間後: -

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

通貨
0.077
買値
0.0757
売値
0.0777
出来高
-
0.00 日の範囲 0.00
0.00 52 週間の範囲 0.00
前日終値
0.077
始値
-
時刻
最終取引時間
平均取引量 (3 か月)
-
財務取引量
-
VWAP
-

OTIC 最新ニュース

Otonomy Announces Change in Stock Exchange Listing

SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq...

Otonomy Provides Corporate Update

SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a...

Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported...

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss

Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baselineLack of activity compared to 0.3 mg dose evaluated in prior studies may be due to a...

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus

OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepointsCompany to discontinue development of OTO-313 and implement other...

Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line...

Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...

Otonomy to Participate in the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...

Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...

Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update

Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
VCIGVCI Global Ltd
US$ 4.1092
(129.56%)
257.58M
IDAIT Stamp Inc
US$ 0.835
(128.77%)
374.4M
WAITop KingWin Ltd
US$ 0.43
(79.17%)
121.92M
HWHHWH International Inc
US$ 0.918
(62.48%)
32.27M
PROCProcaps Group SA
US$ 2.149
(58.01%)
211.74k
PGHLPrimega Group Holdings Ltd
US$ 1.6455
(-98.47%)
43.2M
OTLKOutlook Therapeutics Inc
US$ 1.695
(-65.34%)
61.98M
IMGCIMG Inc
US$ 0.8831
(-44.81%)
5.22M
KDLYKindly MD Inc
US$ 1.075
(-43.12%)
3.54M
HAOHaoxi Health Technology Ltd
US$ 0.13
(-36.59%)
36.86M
IDAIT Stamp Inc
US$ 0.835
(128.77%)
369.69M
VCIGVCI Global Ltd
US$ 4.1092
(129.56%)
257.18M
NVDANVIDIA Corporation
US$ 135.34
(-1.15%)
222.17M
WAITop KingWin Ltd
US$ 0.43
(79.17%)
121.91M
MARAMARA Holdings Inc
US$ 26.915
(7.79%)
87.16M

最近閲覧した銘柄

Delayed Upgrade Clock